Laboratory monitoring and the anti-coagulant effect of Fondaparinux after total knee arthroplasty

Laboratory monitoring and the anti-coagulant effect of Fondaparinux after total knee arthroplasty - Laboratory monitoring and the anti-coagulant effect of Fondaparinux

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017294

Enrollment

Registered

2015-05-15

Start date

2011-01-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients who will be performed TKA/THA

Interventions

Fondaparinux usage (1.5mg) for TKA Fondaparinux usage (2.5mg) for TKA Fondaparinux usage (1.5mg) for THA Fondaparinux usage (2.5mg) for THA no usage of Fondaparinux usage for TKA no usage of Fondapari

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who will be performed TKA/THA more than 20 years old

Exclusion criteria

Exclusion criteria: bleeding risks bleeding tendency bleeding history Operation history within 30 days Renal failure Liver failure History of Hypersensitivity reaction for heparin

Design outcomes

Primary

Measure	Time frame
incidence of DVT	—

Countries

Japan

Contacts

Public ContactTomohiro Onodera

Hokkaido University Graduate School of Medicine Department of Orthopaedic Surgery

tomozou@med.hokudai.ac.jp011-706-5935

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026